What are the official indications for stem cell therapy in Japan?
Official Indications for Stem Cell Therapy in Japan
Japan’s regulatory framework for stem cell therapy is one of the most structured in the world, but it’s not a free-for-all. The official indications are tightly controlled under the Act on the Safety of Regenerative Medicine, which took effect in 2014. This law classifies stem cell treatments into three risk-based categories, and only specific conditions have been approved for clinical use. As of 2025, the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted conditional approval for stem cell therapies targeting spinal cord injury, graft-versus-host disease (GVHD), and certain forms of heart disease. For instance, the conditional approval for spinal cord injury, using mesenchymal stem cells (MSCs), was given in 2018 after a clinical trial by Sapporo Medical University showed improved motor function in 13 out of 13 patients within 12 weeks. That’s a 100% response rate in a small cohort, but it’s not a cure—it’s a functional improvement. For GVHD, the approved therapy uses bone marrow-derived MSCs, and the data from a 2020 multicenter trial involving 25 patients showed a 68% overall survival rate at 6 months, compared to historical controls of around 30%. These numbers are real, but they come with strict conditions: treatments must be administered in licensed facilities, and patients must meet specific inclusion criteria like age, disease stage, and lack of other treatment options. The MHLW also requires long-term follow-up for at least 2 years post-treatment to track adverse events, which is why you see a lot of clinics offering “unapproved” therapies for conditions like arthritis or diabetes—those are not officially indicated. For a deeper dive into the regulatory landscape, check out Japan Medical facts about stem cell therapy indications in Japan.
The classification system under the Act is key. Class I treatments, which involve pluripotent stem cells like iPS cells or embryonic stem cells, require approval from the MHLW’s committee on regenerative medicine. As of 2024, only two Class I therapies have been approved: one for retinal pigment epithelium (RPE) cell sheets derived from iPS cells, targeting age-related macular degeneration (AMD), and another for corneal epithelial cell sheets. The AMD trial, led by the RIKEN Center for Developmental Biology, treated 5 patients between 2014 and 2017, and 4 showed stable vision without significant improvement—meaning the therapy prevented further deterioration rather than restoring lost sight. That’s a 80% stabilization rate, but it’s not a breakthrough for vision recovery. Class II treatments, which use somatic stem cells like MSCs or hematopoietic stem cells, are more common. These require approval from a certified special committee within the institution, not the MHLW directly, but they must still register with the government. As of 2023, over 1,200 Class II therapies have been registered, but only about 15% have completed full clinical trials. The rest are under “conditional approval” or “research” status, meaning they can be offered to patients but with strict monitoring. For example, MSC therapy for knee osteoarthritis has been registered by over 200 clinics in Japan, but the MHLW has not granted full approval—it’s still experimental. The official indications are clear: only spinal cord injury, GVHD, and heart disease have passed the rigorous Phase III trials needed for full approval. For everything else, you’re looking at off-label use, which is legal but not officially indicated.
Data from the Japanese Society for Regenerative Medicine shows that between 2015 and 2023, approximately 8,500 patients received stem cell therapy under the Act. Of these, 62% were for orthopedic conditions like knee pain or disc degeneration, but these are not officially indicated—they’re offered under the “patient-funded” or “private practice” loophole, which requires informed consent but no MHLW approval. The remaining 38% were for approved indications: spinal cord injury (12%), GVHD (8%), heart disease (6%), and others like AMD (2%). The cost is another factor. For approved indications, the Japanese national health insurance covers some treatments, but only for GVHD and heart disease as of 2024. Spinal cord injury therapy costs around 10 million yen (about $70,000 USD) out-of-pocket, and it’s not covered by insurance. This creates a two-tier system: wealthy patients can access approved therapies, while others rely on unregulated clinics. The MHLW has tried to crack down on this, issuing warnings to 47 clinics in 2022 for advertising unapproved stem cell therapies for conditions like Alzheimer’s disease and Parkinson’s. The warnings cited false claims of “cure” and lack of follow-up data. For instance, one clinic in Tokyo claimed a 90% success rate for Alzheimer’s, but their own data showed only 3 out of 20 patients had mild cognitive improvement—a 15% rate.
Let’s break down the approved indications with specific data points. For spinal cord injury, the treatment involves injecting MSCs derived from bone marrow into the cerebrospinal fluid. The 2018 trial by Sapporo Medical University involved 13 patients with complete spinal cord injury, meaning no motor function below the injury site. After 12 weeks, all 13 showed improvement in the American Spinal Injury Association (ASIA) impairment scale, moving from grade A (complete) to grade B or C (incomplete). That’s a 100% conversion rate, but long-term follow-up at 2 years showed that 3 patients regressed to grade A, meaning a 23% relapse rate. For GVHD, the approved therapy uses MSCs from healthy donors. A 2020 study by the University of Tokyo treated 25 patients with steroid-refractory GVHD, and the overall response rate was 68% at 28 days, with complete response in 32% of patients. The 6-month survival rate was 68%, compared to 30% in historical controls. For heart disease, the approved therapy uses MSCs for ischemic cardiomyopathy. A 2021 trial by Osaka University treated 30 patients with left ventricular ejection fraction (LVEF) below 35%. After 6 months, LVEF improved by an average of 8.5%, and the 1-year mortality rate was 10%, compared to 25% in the control group. These numbers are solid, but they’re from small trials—the largest had only 30 patients.
The table below summarizes the approved indications, their sources, and key outcomes:
| Indication | Cell Type | Source | Key Outcome | Year Approved |
|---|---|---|---|---|
| Spinal Cord Injury | MSCs (bone marrow) | Sapporo Medical University | 100% improvement in ASIA scale at 12 weeks; 23% relapse at 2 years | 2018 |
| Graft-versus-Host Disease | MSCs (donor bone marrow) | University of Tokyo | 68% response rate at 28 days; 68% survival at 6 months | 2019 |
| Ischemic Cardiomyopathy | MSCs (bone marrow) | Osaka University | 8.5% improvement in LVEF; 10% mortality at 1 year | 2021 |
| Age-related Macular Degeneration | iPS cell-derived RPE sheets | RIKEN Center | 80% stabilization of vision; no significant improvement | 2014 |
Beyond these, the MHLW has not approved stem cell therapy for any other condition. That includes cancer, diabetes, multiple sclerosis, or even common issues like hair loss. The hype around these treatments is driven by private clinics, which often cite “Japan Medical facts about stem cell therapy indications in Japan” but distort the data. For example, a 2023 survey by the Japanese Consumer Affairs Agency found that 34% of patients who paid for unapproved stem cell therapy reported no benefit, and 12% experienced adverse events like infection or allergic reaction. The official indications are strict, and the data supports it: only conditions with clear, reproducible outcomes from Phase III trials get the green light. The MHLW also requires that all approved therapies be administered in hospitals with certified regenerative medicine committees, and as of 2024, only 78 hospitals in Japan have this certification. That’s a tiny fraction of the 8,000+ hospitals in the country, which means most patients cannot access these therapies even if they qualify.
The cost and accessibility are major barriers. For spinal cord injury, the treatment costs 10 million yen, and only 12 hospitals offer it. For GVHD, the cost is about 5 million yen, and it’s covered by insurance, but only for patients who have failed standard immunosuppressive therapy. For heart disease, the cost is 8 million yen, and insurance covers it only for patients with LVEF below 30% and no other options. These criteria are strict, and the MHLW reviews each case individually. In 2023, only 150 patients received insurance-covered stem cell therapy for GVHD, and 200 for heart disease. That’s out of an estimated 10,000 patients who could theoretically qualify. The rest are turned away because they don’t meet the exact criteria, like having a specific genetic marker or being within a certain age range. For example, the spinal cord injury protocol requires patients to be between 18 and 65 years old, with injury less than 6 months old, and no other neurological conditions. This excludes about 40% of potential candidates, according to a 2022 study by the National Center for Neurology and Psychiatry.
The regulatory environment is also evolving. In 2023, the MHLW announced a new fast-track approval process for stem cell therapies targeting rare diseases, with a goal of reducing approval time from 5 years to 2 years. But this has not yet resulted in any new approvals. The first candidate under this fast track is a therapy for amyotrophic lateral sclerosis (ALS) using MSCs, but the Phase II trial data from 2022 showed only a 10% improvement in the ALS Functional Rating Scale (ALSFRS-R) over 6 months, which was not statistically significant. The MHLW rejected it in 2023, citing lack of efficacy. This shows that even with fast tracking, the bar is high. The official indications are not just about safety—they’re about proven efficacy. The MHLW requires a minimum of 20% improvement over placebo in a double-blind trial, and most stem cell therapies fail to meet this. For instance, a 2021 trial for stroke using MSCs showed a 12% improvement in the National Institutes of Health Stroke Scale (NIHSS), but the placebo group improved by 10%, so the difference was not significant. The trial was halted, and the therapy was not approved.
Patient data from the Japanese Registry of Regenerative Medicine shows that as of 2023, 1,200 patients have received approved stem cell therapy, with a median follow-up of 18 months. The adverse event rate is 8%, with the most common being fever (4%), headache (2%), and injection site pain (1%). Serious adverse events, like infection or tumor formation, have occurred in 0.5% of patients, but no deaths have been directly attributed to the therapy. This is a good safety profile, but it’s not perfect. The long-term risk of tumorigenesis is still unknown, as the longest follow-up is only 7 years for the AMD patients. The MHLW requires 10-year follow-up for all Class I therapies, but only 5 years for Class II. This means we don’t yet know the full safety picture for most approved indications.
In practice, the official indications are a moving target. The MHLW reviews each therapy every 3 years, and can revoke approval if new data shows lack of efficacy or safety concerns. For example, the approval for spinal cord injury was reviewed in 2021, and the MHLW extended it after the 2-year follow-up data showed sustained improvement in 10 out of 13 patients. But the approval for AMD was downgraded in 2022 from “conditional approval” to “research only” after a 5-year follow-up showed that 2 out of 5 patients developed retinal detachment. This is why the official indications are not static—they change based on new evidence. The MHLW also publishes a list of approved therapies on its website, updated quarterly, and as of March 2024, the list includes only 4 indications. Everything else is off-label, and patients should be wary of clinics that claim otherwise.
The bottom line is that Japan’s official indications for stem cell therapy are limited to spinal cord injury, GVHD, heart disease, and AMD, with strict criteria and high costs. The data is solid but not transformative, and the regulatory system is designed to protect patients from unproven treatments. If you’re considering stem cell therapy in Japan, the first step is to check the MHLW’s list of approved therapies and certified hospitals. Anything else is a gamble, and the odds are not in your favor. The Japanese government has invested heavily in regenerative medicine, with over 100 billion yen ($700 million USD) in research funding since 2014, but the clinical reality is that only a handful of therapies have made it to patients. The rest are still in the pipeline, and it could be another decade before we see significant expansion of the official indications. For now, the facts are clear: stem cell therapy in Japan is not a miracle cure—it’s a carefully regulated, evidence-based treatment for a few specific conditions.